OncoMatch/Clinical Trials/NCT06696742

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Is NCT06696742 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Clostridium Butyricum Tablets and Cisplatin for bladder (urothelial, transitional cell) cancer.

Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06696742Data as of May 2026

Treatment: Clostridium Butyricum Tablets · Cisplatin — This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Check if I qualify

Extracted eligibility criteria

Disease stage

Required: Stage T2-T4AN0M0, T3-T4

For Neoadjuvant therapy: T2-T4aN0M0 bladder patients; For Adjuvant therapy: Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systemic chemotherapy

Previously received systemic chemotherapy

Cannot have received: immunotherapy

Previously received...immunotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify